Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Updated data from ongoing Phase 1/1b trial in 1L R/M HNSCC to be presented at 2025 ASCO Annual Meeting
Enrollment ongoing in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC
Strong financial position with approximately $462 million in cash and cash equivalents expected to fund operations into the first half of 2029
BOSTON, May 13, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced financial results for the first quarter ended March 31, 2025 and provided a business update.
"We continued to execute across our clinical programs in the first quarter, maintaining strong momentum as we advance FORTIFI-HN01, the pivotal Phase 2/3 trial of ficerafusp alfa in HPV-negative recurrent/metastatic head and neck squamous cell carcinoma," said Claire Mazumdar, PhD, MBA, Chief Executive Officer of Bicara Therapeutics. "Near term, we look forward to presenting updated data from our ongoing Phase 1/1b clinical trial in this patient population as part of an oral presentation at the 2025 ASCO Annual Meeting. We believe the data have the potential to demonstrate differentiated depth and durability of response driven by the TGF-β arm of ficerafusp alfa. Additionally, we recently presented several datasets at AACR highlighting the broad therapeutic potential of ficerafusp alfa, including translational data that support its potential to prevent resistance mechanisms and potentially prolong durability in HPV-negative patients."
Pipeline Highlights
Bicara is developing ficerafusp alfa, a first-in-class, dual-action bifunctional epidermal growth factor receptor (EGFR)/transforming growth factor beta (TGF-β) antibody for multiple different solid tumor cancer types.
Enrollment is ongoing in FORTIFI-HN01, a global, randomized, double-blind, placebo-controlled, pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab in 1L (first line) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), excluding patients with oropharyngeal squamous cell carcinoma associated with human papillomavirus infection (HPV-positive).
Ongoing Phase 1/1b Clinical Trial in 1L R/M HNSCC
Updated data with extended follow-up from an ongoing Phase 1/1b trial will be highlighted in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held from May 30-June 3, 2025 in Chicago, IL.
Additional Phase 1b expansion cohorts evaluating ficerafusp alfa in 1L R/M HNSCC remain ongoing:
A cohort evaluating 750mg of ficerafusp alfa weekly in combination with pembrolizumab in HPV-negative patients has completed enrollment.
A cohort evaluating 2000mg of ficerafusp alfa every other week in combination with pembrolizumab in HPV-negative patients is enrolling.
A cohort evaluating 1500mg weekly of ficerafusp alfa in combination with pembrolizumab in HPV-neg patients with combined positive scores of 0 is enrolling.
A cohort evaluating ficerafusp alfa in combination with pembrolizumab in HPV-positive patients with a history of heavy smoking is expected to initiate in 2025.
Ongoing Phase 1/1b Expansion Cohorts and Development of Ficerafusp Alfa Across Other HNSCC Populations and Solid Tumor Types
At the American Association for Cancer Research (AACR) Annual Meeting 2025, Bicara presented several datasets that underscore the broad therapeutic potential of ficerafusp alfa. These presentations included:
Preliminary findings from a translational medicine biomarker dataset from Bicara's ongoing Phase 1/1b trial of ficerafusp alfa in 1L R/M HNSCC demonstrated that ficerafusp alfa effectively blocked TGF-β signaling and enabled tumor penetration to modulate key mechanisms associated with drug resistance.
Updated data from an ongoing Phase 1b expansion cohort evaluating ficerafusp alfa monotherapy in patients with second line or later cutaneous squamous cell carcinoma (cSCC) that showed continued single agent activity with an overall response rate (ORR) of 30.4% (7/23 patients) and median progression-free survival of 7.0 months (95% CI, 2.7-8.9 months), demonstrating improvements over historical treatment in cSCC.
New preclinical data offered insights into how TGF-β inhibition may help overcome acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant lung cancer, an important area of unmet need for patients with these types of rat sarcoma (RAS) mutations.
A Phase 1b expansion cohort evaluating ficerafusp alfa both as monotherapy and in combination with pembrolizumab in patients with 3L+ metastatic colorectal cancer (RAS/B-Rapidly Accelerated Fibrosarcoma (BRAF) wild type) is expected to initiate in 2025.
Upcoming Events and Presentations
Details of Bicara's oral presentation at 2025 ASCO Annual Meeting, which will be held from May 30-June 3, 2025 in Chicago, IL, are as follows:
Title: Ficerafusp alfa with pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: Updated results from an expansion cohort of an open-label, multicenter, Phase 1/1b trial
Abstract #: 6017
Session Title: Rapid Oral Abstract Session
Session Category: Rapid Oral Abstract Session
Session Date and Time: 6/1/2025 12:12 - 12:18 p.m. CT
Location: McCormick Place Convention Center
First Quarter 2025 Financial Results
Cash Position: As of March 31, 2025, Bicara had cash and cash equivalents of $462.1 million, compared to $489.7 million as of December 31, 2024. Based on its current operating and development plans, the Company expects that its existing cash and cash equivalents will fund operations into the first half of 2029.
Research and Development Expenses: Research and development expenses were $34.3 million for the first quarter of 2025 as compared to $12.0 million for the first quarter of 2024. The increase was primarily due to additional costs associated with the initiation of FORTIFI-HN01 a pivotal Phase 2/3 clinical trial, as well as the Company's ongoing Phase 1/1b clinical trials to advance ficerafusp alfa.
General and Administrative Expenses: General and administrative expenses were $7.5 million for the first quarter of 2025 as compared to $3.3 million for the first quarter of 2024. The increase was primarily due to additional personnel costs and professional fees to support the advancement of our clinical trials and operations as a public company.
Net Loss: Net loss totaled $36.8 million for the first quarter of 2025 as compared to $12.5 million for the first quarter of 2024.
About Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara's lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-β signaling within the tumor microenvironment. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn or X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'expect,' 'estimate,' 'seek,' 'predict,' 'future,' 'project,' 'potential,' 'continue,' 'target' and similar words or expressions, or the negative thereof, are intended to identify forward-looking statements, although not all contain identifying words. Any statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, Bicara's strategy, business plans and focus; express or implied statements regarding the clinical development of ficerafusp alfa, including Bicara's clinical development of ficerafusp alfa in combination with pembrolizumab and presentation of updated results from an expansion cohort of an open-label, multicenter, phase 1/1b trial of ficerafusp alfa with pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma, the initiation, timing, progress and results of ongoing and planned clinical trials, including the initiation of additional cohorts; the expected therapeutic potential and clinical benefits of ficerafusp alfa, including potential efficacy, depth, durability and tolerability; Bicara's expected operating expenses and capital expenditure requirements, including its cash runway through the first half of 2029; and participation at upcoming conferences and the timing of data readouts. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks and uncertainties that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to uncertainties inherent in the development of product candidates, including the conduct of research activities and the conduct of clinical trials; uncertainties as to the availability and timing of results and data from clinical trials; whether results from prior preclinical studies and clinical trials will be predictive of the results of subsequent preclinical studies and clinical trials; regulatory developments in the United States and foreign countries; whether Bicara's cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Bicara's filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2024, its upcoming Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 and any subsequent filings Bicara makes with the SEC. In addition, any forward-looking statements represent Bicara's views only as of today and should not be relied upon as representing its views as of any subsequent date. Bicara explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Bicara intends to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company's Investor Relations website, in addition to following the Company's press releases, SEC filings, public conference calls, presentations, and webcasts.
Contacts
Investors
Rachel Frank
IR@bicara.com
Media
Amanda Lazaro
1AB
Amanda@1abmedia.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
20 minutes ago
- Globe and Mail
Did Google Just Give Investors a Reason to Load Up on the Stock?
The artificial intelligence (AI) wars are heating up. Companies are investing boatloads of capital in a race to try to stay ahead in this fast-moving technology space, pitting well-financed start-ups like OpenAI versus the large technology giants. One company just threw a sharp shot across the bow: Alphabet (NASDAQ: GOOG)(NASDAQ: GOOGL). The parent company of Google, YouTube, and Google Cloud is putting out new AI products left and right coming from its recent developer conference and has all the tools to win in this new product category. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » And yet, the stock remains cheap and well below all-time highs while other AI-related stocks such as Nvidia soar. Did the company's recent announcements just give investors a reason to buy up this stock? Let's dig in further and find out. Advancements in AI capabilities The number of AI products that Alphabet is working on is staggering. Just last month, the company added new AI features for Google Search, launched shopping in Google AI Mode, debuted its prototype mixed-reality AI glasses, added a lifelike video generator in Veo 3, and much more. Gemini is the crux of Alphabet's AI strategy, the large language model that underpins its AI chatbot application. As of the latest updates, users can talk with Gemini Live, perform computer coding with language prompts, create cinematic videos and images, and virtually try on clothes. Alphabet does not only want to integrate Gemini as a productivity tool, but also help people use it to consume more through the internet such as with online shopping and travel planning. The company is working to monetize these advancements through both subscriptions and advertising. Its Google AI Pro plan is $20 a month, and it just launched Google AI Ultra for $250 a month catered to professionals wanting the latest advancements in AI (for example, video editors). The plan also comes with 30 terabytes of storage, making it a reasonable bundle even at an extreme price for those who need the storage. Like its legacy Google Search business, Alphabet is planning ways to help brands advertise through its AI responses. Some of these tools may disrupt revenue from Google Search. However, overall I believe all of these tools will increase how much people rely on Google products, which will lead to future revenue growth. This contradicts the narrative that Google is losing in AI, which has kept the stock price depressed in recent years and perhaps presents a buying opportunity for investors. Connecting everything together with the Cloud What makes Alphabet's business so beautiful is how its business units all connect together. Its computer chip development helps it process AI workloads and training, which it has been investing in for years now. YouTube can be used to train its AI while its AI products can help people build more content for YouTube, a self-reinforcing loop that can help revenue grow at YouTube and with these Gemini products. Most importantly -- and underpinning all of Alphabet's AI ambition -- is the Google Cloud division. This data center and computing infrastructure can help Alphabet sell its AI tools to third parties while giving it more and more scale. The division is helping the company process so much AI usage while start-ups such as OpenAI have to regularly throttle usage. Alphabet is investing $75 billion this year on capital expenditures, mainly related to Google Cloud and AI. This is the linchpin that gives Alphabet an advantage over AI start-ups and most of the competition. GOOG PE Ratio data by YCharts Should you buy Alphabet stock? Let's bring some of Alphabet's financials to the discussion. Alphabet's revenue was $360 billion over the last 12 months, with the majority coming from Google Search and related properties. Over time, this division may be at risk of slowing growth because of consumers switching to AI tools, but I think the company has plenty of up-and-coming products to replace any lost revenue. Subscriptions and hardware revenue grew 19% year over year last quarter to $10.7 billion, while Google Cloud grew at a blistering pace to $12.26 billion with rapidly expanding profit margins. That, combined that with YouTube as well as Alphabet's revenue coming from products not related to Google Search, should grow to well over $100 billion a year in the near future. Despite predictions of Alphabet's demise, the company is putting up a great fight in AI, which is leading to growing revenue and earnings. Net income has grown 250% in the last five years to $111 billion, which brings the stock's price-to-earnings ratio (P/E) under 19. Management now pays a dividend yielding 0.5% a year and repurchases stock at a rate that has brought down shares outstanding by a cumulative 11% over the last 10 years. Alphabet keeps growing its earnings, is buying back stock, and has a huge opportunity ahead to grow its suite of AI services. These recent product announcements should show investors once again that the stock is a cheap buy today if you plan to hold for a decade or longer. Should you invest $1,000 in Alphabet right now? Before you buy stock in Alphabet, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Alphabet wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor 's total average return is792% — a market-crushing outperformance compared to173%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Brett Schafer has positions in Alphabet. The Motley Fool has positions in and recommends Alphabet and Nvidia. The Motley Fool has a disclosure policy.
Globe and Mail
20 minutes ago
- Globe and Mail
Could Buying Palantir Today Set You Up for Life?
Palantir Technologies (NASDAQ: PLTR) has been around for more than 20 years and in its earlier days was most known for software contracts with government clients. But in recent times, commercial customers have offered this player an exciting new revenue stream, and today, with both government and commercial growth soaring, the future looks bright. Investors have recognized this, and they've been piling into Palantir shares for quite some time. Last year, the stock surged 340%, posting the best performance in the S&P 500. In fact, Palantir's share price has climbed so far and so fast that it's found itself at an eye-popping valuation. Still, earnings have continued to march higher and haven't shown any signs of slowing. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Considering this, could buying Palantir today, even at the current valuation, set you up for life? Let's find out. One of the superstars of the AI boom So, first, a quick summary of Palantir's business. The company, through its software platforms, helps customers aggregate often the most disparate of data to make better use of it. Palantir has integrated artificial intelligence (AI) into this process and two years ago launched its Artificial Intelligence Platform (AIP). This has made the company one of the superstars of the AI boom as both governments and commercial customers raced to get in on this often game-changing tool. AIP can be useful in everything from battlefield operations, immediately identifying risks and implementing key plans, to business needs -- for example, customer United Airlines is using AIP for predictive maintenance, helping the airline avoid delays and millions of dollars in costs. How did Palantir reach so many customers so quickly with AIP? The company launched AIP bootcamps, sessions that allow potential users to go from zero to a use case within hours -- so they can see exactly how AIP could benefit their businesses. All of this has translated into explosive revenue growth, particularly as commercial customers discover that Palantir is no longer a business that primarily serves governments -- instead, its technology has broad applications that also are valuable in the commercial world. In the most recent quarter, U.S. commercial revenue advanced more than 70% to $255 million, and the U.S. commercial business delivered its most valuable quarter, booking total contract value of $810 million. That's up 183% from the year-earlier period. Growth in government and commercial revenue As I mentioned, this is as government revenue continues to climb in the double digits quarter after quarter, so Palantir has conserved the growth of its main revenue stream -- the government business -- and added to it with a newer and high-potential revenue stream -- I say "high potential" because companies across industries are aiming to apply AI to their businesses, and Palantir's AIP makes it easy for them to do this. Importantly, Palantir isn't only focused on revenue gains, but the company also has struck a fantastic balance between growth and profitability -- as seen in its Rule of 40 score. Scores of 40% or higher indicate a software player has balanced these two priorities well, so Palantir's delivery of a score of 83% shows the company is hitting it out of the park. Only about a third of software companies meet this rule, according to McKinsey research, and this further highlights Palantir's accomplishment. All of this is very positive, but now let's look at the one point that's been a thorn in the side of Palantir and its investors: and that's the stock's valuation. Today, it trades for an eye-popping 219 times forward earnings estimates, making some investors question whether they should buy the stock or even stay invested if they've already bought it. At such a valuation, the risk is any disappointment could hurt stock performance. Two important questions So, considering all of this, could this unstoppable (at least so far) stock set you up for life? There actually are two questions here, and the first is: Is Palantir a buy? If you're a value investor, you're sure to find a stock better suited to your strategy elsewhere. But if you're a growth investor and aim to hold on for at least five years, even at today's high valuation it's worth picking up a few Palantir shares. The forward price-to-earnings ratio we looked at, above, considers potential earnings next year -- but not over the long term. Palantir is well positioned to gain as the AI boom continues over the next several years, so even if the stock dips at certain points here and there, you still may benefit greatly from an investment today. As for setting you up for life, this growth stock could help -- but it's never a good idea to depend on one stock on its own to do the whole job. It's much too risky to put all of your eggs in one basket. Instead, supercharge your wealth-building power by investing in several quality stocks and holding on for the long haul. Should you invest $1,000 in Palantir Technologies right now? Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor 's total average return is792% — a market-crushing outperformance compared to173%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025
Globe and Mail
20 minutes ago
- Globe and Mail
2 AI Stocks Down 49% and 86% to Buy Before They Soar, According to Certain Wall Street Analysts
Certain Wall Street analysts see The Trade Desk (NASDAQ: TTD) and Upstart (NASDAQ: UPST) as no-brainer buying opportunities at their current prices, as detailed below: The Trade Desk is 49% below its record high. But Shyam Patil at Susquehanna has set the stock with a target price of $135 per share. That implies 90% upside from its current share price of $71. Upstart is 86% below its record high. But Dan Dolev at Mizuho has set the stock with a target price of $85 per share. That implies 57% upside from its current share price of $54. Here's what investors should know about The Trade Desk and Upstart. The Trade Desk: 90% implied upside The Trade Desk operates the leading independent demand-side platform (DSP), software that helps media buyers plan, measure, and optimize ad campaigns. The Trade Desk is considered an independent ad tech company because it does not own media content and, therefore, has no reason to steer media buyers toward specific ad inventory. That differentiates the company from rivals such as Alphabet 's Google and Meta Platforms. Importantly, The Trade Desk was recognized as a DSP technology leader in recent reports from Forrester Research and Frost & Sullivan. Analysts mentioned its dominance in connected TV advertising and its use of artificial intelligence (AI) as key strengths. The company in 2023 announced Kokai, a platform upgrade featuring new AI capabilities that optimize the digital media buying process, helping advertisers buy the right impression at the right price to reach the right audience. In addition, The Trade Desk has a strong position in retail advertising, where partnerships with industry giants such as Albertsons, Dollar General, and Walmart provide the company with data that creates unique measurement opportunities on its platform. CEO Jeff Green recently told analysts, "We are convinced that based on the current landscape and current competitive set, we are the best positioned to win the lion's share of market share." Wall Street expects The Trade Desk's earnings to increase at 12% annually through 2026. That puts the current valuation of 31 times earnings between reasonable and expensive, but the company may perform better than the average analyst anticipates. The Trade Desk beat the consensus earnings estimate by an average of 11% in the last six quarters, and ad tech spending is forecast to increase at 14% annually through 2030. Here's the takeaway: The Trade Desk has a strong competitive position in a quickly growing industry. Shares are not cheap today, nor are they absurdly expensive. Of course, there is no guarantee the stock ever regains its previous record high, but patient investors should feel comfortable buying a small position. Upstart: 57% implied upside Upstart provides a lending platform that leans on artificial intelligence to help banks and credit unions quantify credit risk more accurately than traditional credit scores. Its machine learning models analyze thousands of signals across millions of repayment events to identify fraud and estimate the odds of default. Comparatively, traditional models consider a few dozen variables at most. Upstart says its AI models can approve more borrowers at lower interest rates than tradition underwriting models, which means its platform lets lenders operate more profitably. That value proposition should only strengthen over time. Its platform benefits from a network effect whereby the underlying AI models become more intelligent each time a borrower makes or misses a payment. As a caveat, Upstart is highly sensitive to interest rates. Loan originated on its platform during the last eight quarters delivered annual returns that exceeded the 2-year Treasury yield by more than 8 percentage points. That is a compelling return on investment, but the risk profile would change if the Federal Reserve raises interest rates, and Upstart would likely see less demand for its platform. Nevertheless, Wall Street estimates the company's adjusted earnings will increase at 195% annually through 2026. That makes the current valuation of 165 times earnings look reasonable. Additionally, the stock currently trades at 6.9 times sales, a discount to the one-year average of 7.3 times sales. Here's the takeaway: As with The Trade Desk, there is no guarantee Upstart ever regains its previous record high. But the company has a compelling value proposition for banks and credit unions, which should drive adoption of its AI lending platform over time. Long-term investors should feel comfortable buying a small position today. Should you invest $1,000 in The Trade Desk right now? Before you buy stock in The Trade Desk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and The Trade Desk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor 's total average return is792% — a market-crushing outperformance compared to173%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. Trevor Jennewine has positions in The Trade Desk. The Motley Fool has positions in and recommends Alphabet, Meta Platforms, The Trade Desk, Upstart, and Walmart. The Motley Fool has a disclosure policy.
